|
The United States Food and Drug Administration (USFDA) conducted inspection at the company's active pharmaceutical ingredients (APIs) facility at Roha from 9 to 12 September 2019. The inspection was a post approval inspection and successfully concluded without any FDA form 483 issued.
Meanwhile, the S&P BSE Sensex was down 41 points or 0.11% to 37,063.11.
On the BSE, 6083 shares were traded in the counter so far compared with average daily volumes of 6359 shares in the past one quarter. The stock hit a high of Rs 187 and a low of Rs 182.2 so far during the day.
The stock hit a 52-week high of Rs 227 on 30 Oct 2018. The stock hit a 52-week low of Rs 158.35 on 31 Jul 2019.
On a consolidated basis, Unichem Lab reported a net loss of Rs 6.19 crore in Q1 June 2019 over a net loss of Rs 20.46 crore in Q1 June 2019 over Q1 June 2018.
Unichem Laboratories is a pharmaceutical company addressing the needs of relevant and growing therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.
|